Keros Therapeuticsincis A Clinical Stagebiopharmaceutical Company Based In Lexingtonmassachusettsfounded In 2015Thecompany Is Dedicated To Discovering And Developing Innovativetreatments For Disorders Related To Dysfunctional Signaling Of Thetransforming Growth Factor Betatgf I Family Of Proteinskeros Therapeutics Went Public On April 82020 Thecompany Focuses On Rarehematologic And Musculoskeletal Disorders With Significant Unmet Medical Needsits Product Pipelineincludes Ker 050Aimed At Treating Low Blood Cell Counts In Patients With Myelodysplastic Syndromes And Myelofibrosisker 012Currently In Phaseii Trialstargets Pulmonary Arterial Hypertension And Cardiovascular Disordersker 065 Is In Phasei Trials For Neuromuscular Diseaseswith A Focus On Duchennemuscular Dystrophykeros Therapeutics Also Collaborates With Hansoh Healthtech To Develop And Commercializeelritercept And Related Productsjasbir Seehra Is Thechair And Ceoleading A Team Of Approximately 169 Employees In Thebiotechnology Sector
No conferences found for this company.
| Company Name | Karos Pharmaceuticals Inc |
| Country |
United States
|
| Address | 5 Science Park 2 New Haven Connecticut 06511 United States |
| Telephone | Login to View |
| Login to View |
